But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Fexlamose is being developed as a chronic treatment for COPD and asthma in conjunction with standard therapies, to improve ...

Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.

Discover the top 19 most notable drugs approved by the FDA in 2024, including Dupixent for COPD and FluMist for self-administration. See the full list here.

Tyr Pharma's stock surged on positive data for pulmonary sarcoidosis treatment, but cash balance risk keeps investors ...

Scotland has the highest rate of drugs deaths in Europe, with fatalities rising by 12 in a year to 1,172 drug-related deaths in 2023.

PAH is a rare condition in children, but is often fatal if left untreated, and protocols for pediatric patients have not been ...

A new era, where AI is at the centre of the drug discovery process is emerging, says Charlotte Deane, a professor of ...

Chief executive David Zaccardelli said Ohtuvayre was off to an "exceptionally strong start," with more than 3,500 healthcare ...

Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...

The Dr Trust Bestest Compressor Nebulizer is a highly efficient and reliable device for home use. It features a powerful ...